Barragan CR, Remolina BYA, Montenegro RE, Bourlon CRA, Bourlon MT

Language: Spanish
References: 15
Page: 342-346
PDF size: 131.60 Kb.

ABSTRACT

Clear cell renal carcinoma (CCRC) represents 3% of worldwide overall cancer cases. 14.5% of patients in Latin America are diagnosis with de novo metastatic disease, and about 30% of localized cases present a systemic recurrence. The International Metastatic CCRC Database Consortium classifies patients according to favorable, intermediate, and poor prognosis at the time of diagnosis. Given the biological variability of the disease, treatment strategies go from active surveillance to systemic therapy with immunotherapy-based combinations. In this review, we highlight the criteria to consider in the selection of treatment in advanced CCRC. Furthermore, we highlight recent data arising from clinical trials that led to changes in the treatment paradigm.

REFERENCES

1. Abreu D, Carvalhal G, Gueglio G, Tobia I, Garcia P, Zuñiga A et al. Prognostic factors in de novo metastatic renal cell carcinoma: a report from the Latin American Renal Cancer Group. JCO Glob Oncol. 2021; 7: 671-685.

2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356 (2): 115-124.

3. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018; 378 (14): 1277-1290.

4. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27 (34): 5794-5799.

5. Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016; 17 (9): 1317-1324.

6. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001; 345 (23): 1655-1659.

7. Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018; 379 (5): 417-427.

8. Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 2019; 5 (2): 164-170.

9. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019; 380 (12): 1116-1127.

10. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021; 384 (9): 829-841.

11. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021; 384 (14): 1289-1300.

12. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013; 49 (6): 1287-1296.

13. Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20 (1): 71-90.

14. Stukalin I, Connor Wells J, Fraccon A, Pasini F, Porta C, Lalani AKA et al. Fourth-line therapy in metastatic renal cell carcinoma (mRCC): results from the international mRCC database consortium (IMDC). Kidney Cancer. 2018; 2 (1): 31-36.

15. George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M et al. Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the alliance A031203 CABOSUN trial. Oncologist. 2019; 24 (11): 1497-1501.